Contents 3 min read

Claim and source comparison

Comparison limited to two acute human experiments, an Alzheimer trial, a rat-brain enzyme experiment and EMA information. It does not review every source or all clinical claims.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

<strong>Kennedy et al. (2002)</strong> compared single 300, 600 and 900 mg lemon-balm extract doses with placebo in 20 healthy young adults. Attention accuracy improved at 600 mg, while some memory measures worsened by dose and time, and alertness fell at 900 mg. The separate <strong>2004</strong> laboratory-stress trial used <strong>300 and 600 mg</strong> in 18 healthy people; 600 mg increased calmness and reduced alertness. These findings do not establish general cognitive improvement or treatment of anxiety.

These are small, acute, product-specific crossover experiments. Increased calmness does not erase worsening on some memory measures or establish disease treatment, long-term benefit or safe combinations.

Source 1 · Source 4 · Abstract read

Human randomized controlled trial

Noguchi-Shinohara et al. (2020) examined a lemon balm extract containing 500 mg of rosmarinic acid daily for 24 weeks in 23 Alzheimer patients. No serious adverse effects occurred, and cognitive measures did not differ significantly. This small trial does not exclude rare or long-term harm; the dose is not equivalent to 500 mg of ordinary lemon balm extract.

The primary endpoint was safety and tolerability. No cognitive difference in a small sample does not exclude every possible effect; a neuropsychiatric-measure difference does not establish halted disease progression.

Source 5 · Abstract read

Cell / laboratory study

Awad et al. (2009) tested a methanolic lemon-balm extract in vitro against rat-brain GABA transaminase. Rosmarinic, ursolic and oleanolic acids were isolated from active fractions.

This is not a human experiment. Enzyme inhibition does not demonstrate increased GABA in the human brain, clinical anxiety treatment or a specific interaction with sedative medicines.

Source 6 · Abstract read

Regulatory scientific assessment

The EMA monograph describes inhibition of thyroid-stimulating hormone (TSH) activity as an in vitro and animal finding with a water extract; clinical relevance is unknown. This is not proven inhibition of human thyroid-hormone synthesis. Discuss uncertainty with a doctor or pharmacist if you have thyroid disease or medication.

A preclinical finding is not a verified human interaction or a reason to change medication doses. Missing interaction data is not evidence that combined use is safe.

Source 7 · Official summary read

Regulatory scientific assessment

The EMA assessment addresses lemon balm for stress and sleep on the basis of traditional use rather than established clinical efficacy. The monograph notes possible driving impairment, no available drug-interaction data and unestablished pregnancy/breastfeeding safety.

Traditional-use registration does not verify clinical benefit. Reduced alertness is possible; affected people should not drive. Missing data proves neither a specific interaction nor a safe combination.

Source 7 · Official summary read

Our evidence and source methodology

Melissa: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Melisa?

Small human studies have examined lemon balm for calmness and stress measures; general cognitive superiority or treatment of anxiety has not been established. Extracts are not interchangeable, and the GABA-T mechanism does not guarantee overall safety.

Mechanism of Effect

Awad et al. (2009) tested a methanolic lemon-balm extract in vitro against rat-brain GABA transaminase. Rosmarinic, ursolic and oleanolic acids were isolated from active fractions.

This is not a human experiment. Enzyme inhibition does not demonstrate increased GABA in the human brain, clinical anxiety treatment or a specific interaction with sedative medicines.

Clinical Evidence

Kennedy et al. (2002) compared single 300, 600 and 900 mg lemon-balm extract doses with placebo in 20 healthy young adults. Attention accuracy improved at 600 mg, while some memory measures worsened by dose and time, and alertness fell at 900 mg. The separate 2004 laboratory-stress trial used 300 and 600 mg in 18 healthy people; 600 mg increased calmness and reduced alertness. These findings do not establish general cognitive improvement or treatment of anxiety.

These are small, acute, product-specific crossover experiments. Increased calmness does not erase worsening on some memory measures or establish disease treatment, long-term benefit or safe combinations.

Noguchi-Shinohara et al. (2020) examined a lemon balm extract containing 500 mg of rosmarinic acid daily for 24 weeks in 23 Alzheimer patients. No serious adverse effects occurred, and cognitive measures did not differ significantly. This small trial does not exclude rare or long-term harm; the dose is not equivalent to 500 mg of ordinary lemon balm extract.

The primary endpoint was safety and tolerability. No cognitive difference in a small sample does not exclude every possible effect; a neuropsychiatric-measure difference does not establish halted disease progression.

Controlled studies have not adequately established the efficacy and safety of these combinations in healthy people. Theoretical complementarity is not proven synergy or a recommendation to combine them.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

The EMA assessment addresses lemon balm for stress and sleep on the basis of traditional use rather than established clinical efficacy. The monograph notes possible driving impairment, no available drug-interaction data and unestablished pregnancy/breastfeeding safety.

Traditional-use registration does not verify clinical benefit. Reduced alertness is possible; affected people should not drive. Missing data proves neither a specific interaction nor a safe combination.

The EMA monograph describes inhibition of thyroid-stimulating hormone (TSH) activity as an in vitro and animal finding with a water extract; clinical relevance is unknown. This is not proven inhibition of human thyroid-hormone synthesis. Discuss uncertainty with a doctor or pharmacist if you have thyroid disease or medication.

A preclinical finding is not a verified human interaction or a reason to change medication doses. Missing interaction data is not evidence that combined use is safe.

Sources

  1. Kennedy DO, et al. (2002). Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology Biochemistry and Behavior, 72(4), 953–964. PubMed · PMID 12062586
  2. Cases J, et al. (2011). Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterranean Journal of Nutrition and Metabolism, 4(3), 211–218. PubMed · PMID 22207903
  3. Scholey A, et al. (2014). Anti-stress effects of lemon balm-containing foods. Nutrients, 6(11), 4805–4821. PubMed · PMID 25360512
  4. Kennedy DO, Little W, Scholey AB. (2004). Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic Medicine, 66(4), 607–613. https://doi.org/10.1097/01.psy.0000132877.72833.71 PubMed · PMID 15272110
  5. Noguchi-Shinohara M, et al. (2020). Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. Scientific Reports, 10(1), 18627. doi:10.1038/s41598-020-73729-2. PubMed · PMID 33122694
  6. Awad R, et al. (2009). Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytotherapy Research, 23(8), 1075–1081. PubMed · PMID 19165747
  7. European Medicines Agency. Community herbal monograph on Melissa officinalis L., folium. https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-melissa-officinalis-l-folium_en.pdf European Medicines Agency

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions